Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - CorMedix Inc. | crmd_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 27, 2014
|
CORMEDIX INC.
|
|
(Exact Name of Registrant as Specified in Charter)
|
|
Delaware
|
001-34673
|
20-5894890
|
||
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
745 Rt. 202-206, Suite 303, Bridgewater, NJ
|
08807
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (908) 517-9500
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01.
|
Other Events.
|
On October 27, 2014, CorMedix issued a press release announcing approval from the United States Food and Drug Administration to initiate a clinical trial for Neutrolin® in the U.S.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release dated October 27, 2014. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORMEDIX INC. | |||
|
Date: October 27, 2014
|
By:
|
/s/ Randy Milby | |
| Name: Randy Milby | |||
| Title: Chief Executive Officer | |||
3